Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce that it has been granted a European patent for its novel reference method which can be used to accurately assign values to calibrators used in diagnostic assays for the determination of the concentration of NT-proBNP in blood samples.
Gentian has been informed that our international patent application PCT/EP2022/077433 entitled “Novel method for determining a concentration of N-terminal pro-hormone BNP (NT-proBNP) in a sample” is patentable in its entire set of claims. The patent application will now enter the national and regional phases, where validated patents will be issued in the designated nations and regions. The patented method utilizes a robust mass spectrometry-based approach, specifically LC-MS/MS, to quantify the total amount of NT-proBNP in a sample, regardless of its glycosylation status. This advanced technique provides a reliable reference method, which can be used to calibrate NT-proBNP immunoassays and harmonize existing NT-proBNP diagnostic methods, ensuring higher accuracy and reliability.
“Our new method can support more reliable clinical measurements of NT-proBNP”, says Njaal Kind, acting CEO of Gentian Diagnostics ASA. ”With this patented reference method, Gentian demonstrates its commitment to the development of harmonized NT-proBNP measurements which may be of significant benefit to healthcare providers and patients”.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.
IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)